Fate Therapeutics Taps Laura Hamill, Former Gilead EVP, to Guide $22B Strategy
FATE•Fate Therapeutics appointed Laura Hamill to its Board, leveraging her 30+ years of commercial leadership as the company advances its iPSC-derived therapy pipeline toward later-stage development. Hamill previously led Gilead’s commercial operations overseeing $22 billion revenue and 2,500 staff, and directed Amgen’s U.S. unit representing 80% of revenue.
1. Board Appointment Details
Fate Therapeutics appointed Laura Hamill to its Board of Directors, marking a strategic move as the company transitions toward a commercial-stage biopharmaceutical enterprise. Hamill will support decision-making as the firm advances its iPSC-derived cellular immunotherapies into later-stage development.
2. Commercial Leadership Background
Hamill brings over 30 years of biopharmaceutical commercial experience, including her tenure as Executive Vice President, Worldwide Commercial Operations at Gilead where she oversaw $22 billion in annual revenue and 2,500 employees. Earlier, she led Amgen’s U.S. operations unit responsible for 80% of company revenue and 2,000 staff.
3. Strategic Impact on Commercialization
Her expertise in strategic planning, market development, product launches, pricing, and market access is expected to strengthen Fate’s commercial capabilities. The board hopes her insight will accelerate the launch readiness of the company’s off-the-shelf iPSC-derived T-cell and NK cell therapies.
